Mangoceuticals, Inc. to acquire Nuclea Energy Inc.

Mangoceuticals, Inc. and Nuclea Energy Inc. have agreed to merge in a transaction structured as a merger of equals. The deal, which was announced on 29 July 2026, involves the combination of two entities operating within the energy sector. The buyer is based in the United States, while the target is headquartered in Canada. Consideration for the transaction will be provided through the issuance of shares. No financial details regarding the value of the deal have been disclosed to the public, and the specific currency for any reported figures remains unreported. The confidence level associated with the reported value is low, indicating that precise monetary terms are not yet available for verification. This structure suggests a collaborative approach to combining the assets and operations of both companies, rather than a traditional acquisition where one party purchases the other outright. The focus remains on the structural arrangement and the mutual agreement to proceed with the merger.

The transaction is currently at the firm intention stage. This status indicates that both parties have committed to the deal but have not yet completed all necessary steps for final closure. The completion date has not been determined, and no specific timeline for the finalisation of the merger has been provided. Regulatory approvals and other standard closing conditions are likely required before the deal can be fully executed. Stakeholders should note that the lack of disclosed financial terms means the economic impact of the merger remains unclear at this stage. The parties are expected to continue negotiations and preparations to finalise the terms of the share-based consideration. Further updates will be necessary once the transaction moves beyond the current intention phase and towards a definitive agreement.